Follow-up study of patients treated with olanzapine pamoate in France in real-life treatment situation

Chartier, F.; Rouillon, F.; Berggren, Lovisa; Jamonneau, I; Falissard, Bruno; Llorca, Pierre Michel

doi:10.1016/j.encep.2017.05.004

Cited by 3 publications

(7 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The discontinuation rate in the study by Chartier et al . was about 40% . The main reasons leading to discontinuation were physician/patient decision, loss to follow‐up, and occurrence of adverse events.…”

Section: Resultsmentioning

confidence: 99%

“…In fact, there were no significant differences in the discontinuation rate between patients treated with oral OLA and those treated with the depot formulation . In other long‐term, open‐label studies, the discontinuation rate in patients treated with OLA‐LAI ranged between 36% and 58% . The main causes of dropout were patient decision, adverse events, and clinical relapse…”

Section: Discussionmentioning

confidence: 98%

“…In other long‐term, open‐label studies, the discontinuation rate in patients treated with OLA‐LAI ranged between 36% and 58% . The main causes of dropout were patient decision, adverse events, and clinical relapse…”

Section: Discussionmentioning

confidence: 99%

“…38 In other long-term, open-label studies, the discontinuation rate in patients treated with OLA-LAI ranged between 36% and 58%. 39,40 The main causes of dropout were patient decision, 38,39 adverse events, 38,40 and clinical relapse. 38 The most significant finding emerging from the reviewed studies on PP1M was that the drug showed lower (or, at best, similar) dropout rates in all but one head-to-head comparison with several comparators, such as RIS-LAI, FGA-LAI, and both FGA and SGA in oral formulation.…”

Section: Discussionmentioning

confidence: 99%

“…35 ARI-LXL is a new formulation of ARI-LAI, available in the range of dosages between 441 and 882 mg. At time of writing, no long-term studies on ARI-LXL have been published. 19,37 OLA-LAI (Table 2 [38][39][40] ) OLA-LAI is the pamoate salt of OLA. 41 Detke et al 38 compared times to all-cause discontinuation in outpatients diagnosed with SCZ spectrum disorders at risk for relapse treated with OLA-LAI or oral OLA.…”

Section: Ari-lai and Ari-lxlmentioning

confidence: 99%

See 4 more Smart Citations

Discontinuation rates during long‐term, second‐generation antipsychotic long‐acting injection treatment: A systematic review

Gentile

2019

Psychiatry Clin Neurosci

View full text Add to dashboard Cite

Aim The aim of this review was to analyze the discontinuation rates during long‐term treatment with second‐generation antipsychotic long‐acting injection (SGA‐LAI) in adults with either schizophrenia spectrum or bipolar disorders. Methods A systematic search (PubMed, Scopus, and the Cochrane Library) of studies published in English (1 January 2001–12 October 2018) identified 1214 abstracts, which were analyzed independently by the author and two colleagues. Studies were retrieved and reviewed if they reported primary data on the discontinuation rate before the study end during treatment lasting ≥36 weeks. Data were extracted from 51 articles meeting the inclusion criteria. Results In all head‐to‐head comparisons, and studies on patients with schizophrenia spectrum or bipolar disorders, the discontinuation rate before the study end in patients treated with SGA‐LAI was, at best, similar to that recorded in patients treated with first‐generation antipsychotics in either oral or LAI formulations or with oral SGA. In particular, in most of the SGA‐LAI long‐term studies, the rate of premature dropout was higher than 50%. Conclusion Reviewed data suggest that SGA‐LAI show no clear superiority over less expensive drugs (including first‐generation antipsychotic LAI and oral antipsychotic formulations) in reducing the risk of premature antipsychotic discontinuation. Thus, alternative strategies should be considered to improve medication persistence and lower discontinuation rates in patients with severe psychiatric disorders. Planning tailored, individualized, and integrated approaches (including frequent clinical evaluations, and behavioral or other flexible techniques adaptable to different settings and patients) may be an effective intervention for improving patient adherence in long‐term pharmacological treatment regimens.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 98%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Ari-lai and Ari-lxlmentioning

confidence: 99%

See 3 more Smart Citations

Discontinuation rates during long‐term, second‐generation antipsychotic long‐acting injection treatment: A systematic review

Gentile

2019

Psychiatry Clin Neurosci

View full text Add to dashboard Cite

show abstract

Production of biodegradable rods of polycaprolactone/olanzapine for potential application in treatment of Schizophrenia

Almeida

Patricio

Garcia

et al. 2021

J of Applied Polymer Sci

View full text Add to dashboard Cite

Olanzapine (OLZ) is a commonly antipsychotic used to treat schizophrenia, a mental illness, with fewer side effects when compared with other drugs of the same class. It is commercialized mainly as oral tablets and orally disintegrating tablets. However, this drug oral bioavailability is affected by the first pass effect and low solubility in water. This requires high daily doses that can cause more side effects and poor treatment compliance. Also, the frequency of frequency of tablet intake is commonly related to patients' abandonment of schizophrenia treatment. So, the development of implantable biomaterials for OLZ delivery can be an alternative to solve both problems, since this material can, potentially, be used subcutaneously in less frequent administrations, thus the treatment has a greater chance of success. Therefore, the objective of this work was to produce polycaprolactone (PCL) rods incorporated with OLZ by hot‐melt extrusion technique. The rods were characterized by different techniques, which showed an amount of 6.78 ± 0.56 mg of OLZ per rod. The in vitro release studies were performed and they showed a controlled release of the drug that followed the Higuchi's model. These results indicated that the PCL/OLZ rods have potential application in the schizophrenia treatment.

show abstract

Olanzapine

2017

Reactions Weekly

View full text Add to dashboard Cite

Follow-up study of patients treated with olanzapine pamoate in France in real-life treatment situation

Cited by 3 publications

References 25 publications

Discontinuation rates during long‐term, second‐generation antipsychotic long‐acting injection treatment: A systematic review

Discontinuation rates during long‐term, second‐generation antipsychotic long‐acting injection treatment: A systematic review

Production of biodegradable rods of polycaprolactone/olanzapine for potential application in treatment of Schizophrenia

Olanzapine

Contact Info

Product

Resources

About